X

Trial Profile

A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Bexarotene
Indications Cutaneous T-cell lymphoma
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

01 Sep 2009 Actual initiation date changed from Aug 2005 to Sep 2005 as reported by ClinicalTrials.gov.
18 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
26 May 2009 Actual initiation date changed from Sep 2005 to Aug 2005 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com